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Abstract
Cardiovascular diseases represent the main cause of mortality in the industrialized world and the identification of
effective preventive strategies is of fundamental importance. Sulforaphane, an isothiocyanate from cruciferous
vegetables, has been shown to up-regulate phase II enzymes in cardiomyocytes and counteract oxidative stress-
induced apoptosis. Aim of the present study was the identification and characterization of novel sulforaphane targets
in cardiomyocytes applying a proteomic approach. Two-dimensional gel electrophoresis and mass spectrometry were
used to generate protein profiles of primary neonatal rat cardiomyocytes treated and untreated with 5 µM
sulforaphane for 1-48 h. According to image analysis, 64 protein spots were found as differentially expressed and
their functional correlations were investigated using the MetaCore program. We mainly focused on 3 proteins:
macrophage migration inhibitory factor (MIF), CLP36 or Elfin, and glyoxalase 1, due to their possible involvement in
cardioprotection. Validation of the time-dependent differential expression of these proteins was performed by western
blotting. In particular, to gain insight into the cardioprotective role of the modulation of glyoxalase 1 by sulforaphane,
further experiments were performed using methylglyoxal to mimic glycative stress. Sulforaphane was able to
counteract methylglyoxal-induced apoptosis, ROS production, and glycative stress, likely through glyoxalase 1 up-
regulation. In this study, we reported for the first time new molecular targets of sulforaphane, such as MIF, CLP36
and glyoxalase 1. In particular, we gave new insights into the anti-glycative role of sulforaphane in cardiomyocytes,
confirming its pleiotropic behavior in counteracting cardiovascular diseases.
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Introduction
Coronary heart disease represents the main cause of
mortality in the industrialized world, being responsible of over
40% of all deaths in Western Europe and United States [1].
Many studies have shown a critical role for oxidative stress in
various forms of cardiovascular diseases, including myocardial
ischemia-reperfusion (I/R) injury, congestive heart failure,
atherosclerosis, and chemical-induced cardiotoxicity [2,3]. An
emerging strategy to counteract oxidative cardiac damage is
the up-regulation of endogenous antioxidants and phase II
enzymes in cardiac cells by synthetic and naturally occurring
agents [4,5]. Among them, sulforaphane (SF) (1-
isothiocyanate-(4R)-(methylsulfinyl)butane) is one of the most
promising diet-derived indirect antioxidant agents [6,7]. SF is
produced by the breakdown of glucoraphanin, a glucosinolate
abundantly present in some Cruciferous vegetables, especially
broccoli [8]. It has been reported that broccoli protects hearts
against I/R injury through the redox cycling of the thioredoxin
superfamily [9]. A study conducted in 12 healthy subjects has
shown that only one-week intake of broccoli sprouts improved
cholesterol metabolism and decreased oxidative stress
markers [10]. Moreover, broccoli consumption was strongly
associated with reduced risk of cardiovascular heart disease
death in postmenopausal women [11]. We have recently
demonstrated that SF protects cardiomyocytes against
apoptosis induced by oxidative stress [12]. In particular, SF
cardioprotection was related to the up-regulation of a panel of
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key cellular antioxidants and phase II enzymes, including
glutathione, glutathione reductase, glutathione-S-transferase,
thioredoxin reductase, and NAD(P)H:quinone oxidoreductase
1, but other mechanisms could be involved in SF
cardioprotective effects.
The present study aimed to identify and characterize novel
targets of SF using a proteomic approach based on two-
dimensional gel electrophoresis (2-DE) and mass spectrometry
(MS). We focused our attention on 3 proteins: macrophage
migration inhibitory factor (MIF), CLP36, and lactoylglutathione
lyase, also known as glyoxalase 1 (GLO1), due to their
possible involvement in cardioprotection and, in particular, on
the cardioprotective role of GLO1 up-regulation by SF. In
normal physiological condition GLO1 controls methylglyoxal
(MG) homeostasis [13]. MG is the most investigated advanced
glycation end product (AGE) precursor. AGEs are a
heterogeneous group of molecules that are generated through
non-enzymatic glycation and oxidation of proteins, lipids and
nucleic acids [14]. Studies have shown that GLO1
overexpression has beneficial effects, such as prevention of
myocardial cell death during reperfusion and delay of aging
and senescence [15,16].
Our results suggested that SF cardioprotection is a complex
mechanism involving not only the induction of phase II
enzymes [12,17], but also unexpected proteins with anti-
apoptotic role [18], acting as adapters between kinases and
cytoskeleton [19], and counteracting AGE production.
Materials and Methods
Materials
PhosSTOP was purchased from Roche Diagnostics
(Mannheim, Germany). D,L-Sulforaphane (SF) was obtained
from LKT Laboratories (Minneapolis, MN, USA). Anti-CLP36,
anti-glyoxalase I (GLO1) and anti-macrophage migration
inhibitory factor (MIF) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-caspase-3, anti-
rabbit and anti-mouse peroxidase-conjugated antibodies were
from Cell Signaling Technology (Beverly, MA, USA).
Pharmalyte, pH 3-10, and ECL® Advance reagent were
obtained from GE Healthcare (Buckinghamshire, UK). Bio-Rad
protein assay dye reagent was purchased from Bio-Rad
(Hercules, CA, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 2’,7’-
dichlorodihydrofluorescein diacetate (DCFH-DA), 2,2-azinobis-
(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), bovine serum
albumin (BSA), reduced glutathione (GSH), dimethyl sulfoxide
(DMSO), DMEM F12, fetal calf serum (FCS), horse serum
(HS), Gentamicin, Amphotericin B, anti-β-actin, and all other
chemicals of the highest analytical grade were purchased from
Sigma-Aldrich (Milan, Italy). 3,8-phenanthridinediamine, 5-(60-
triphenylphosphoniumhexyl)-5,6 dihydro-6-phenyl (MitoSOX)
was purchased from Invitrogen (Paisley, UK). Dihydroethidium
(DHE) was purchased from Molecular Probes (Eugene, OR,
USA).
Ethics Statement
The investigation conforms with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996)
and approved by the Ethics Committee of our Institution
(Comitato Etico Scientifico per la Sperimentazione Animale,
Alma Mater Studiorum - Università di Bologna).
Cell culture and treatments
Neonatal Wistar rat cardiomyocytes were isolated as
previously reported [20]. Briefly, cells were obtained by
isolation of cardiomyocytes from the ventricles of 2–4 days old
Wistar rats, seeded at a density of 1x105 cells/cm2 and grown
until confluence in DMEM F12 supplemented with 10% v/v FCS
and 10% v/v HS. Cells were treated with 5 μM SF for different
time points, and control cells were treated with equivalent
concentrations of DMSO alone. SF concentration utilized in this
study is readily achievable in rat and human plasma [21,22]
and is close to that achievable in human plasma after a single
portion of broccoli sprout isothiocyanate intake [23].
Protein extraction
SF-treated and control cells were washed twice with cold
PBS and twice with 10 mM Tris-HCl/250 mM sucrose pH 7.4 to
remove salts. Cells were lysed in rehydration buffer, incubated
for 1 h at room temperature and stored at -80°C. After thawing,
samples were centrifuged at 18,000 g at 4°C for 15 min and the
supernatant was immediately used or aliquoted and frozen at
-20°C. Protein concentration was determined according to the
Bradford method [24].
Two-dimensional gel electrophoresis and image
analysis
At confluence, cardiomyocytes were treated with 5 µM SF or
the DMSO vehicle control for 1, 6, 24 and 48 h. Isoelectric
focusing (IEF) was carried out on Immobiline DryStrips (GE
Healthcare, Buckinghamshire, UK), 13 cm long, with a pH 3-10
linear gradient, using an IPGphor apparatus (GE Healthcare).
For analytical runs: IPG strips were rehydrated with 200 μg of
protein in 250 μL of IPG rehydratation solution (8 M urea, 2%
CHAPS, 10 mM DTT, 1% v/v Pharmalyte and trace
bromophenol blue) for 12 h at 50 V. The strips were then
focused according to the following voltage steps: 1 h at 500 V,
1 h at 1000 V, 30-min ramp up to 8000 V, and 2 h at 8000 V
until a total of 19 kVh was reached.
For mass spectrometry (MS)-preparative runs: IPG strips
were overnight rehydrated in 8 M urea, 4% CHAPS, 1% DTE,
1% v/v Pharmalyte, and a trace of bromophenol blue. IEF was
performed by applying 1000 μg of protein using the sample cup
loading system (GE Healthcare) at the cathodic end of strips.
Running conditions were as follows: 200 V for 24 h, 500 V for
30 min, 1250 V for 1 h, from 1250 to 3500 V in 1 h, 3500 V for
3 h, from 3500 to 5000 V in 1 h, 5000 V for 6 h, from 5000 to
8000 V in 2 h, and 8000 V until reaching a total of 100 kVh.
Prior to the second dimension run, analytical and preparative
gel strips were equilibrated sequentially in two equilibration
buffered solutions (50 mM Tris-HCl pH 6.8, 6 M urea, 30%
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glycerol, 2% SDS), one containing 2% DTE, and the other
2.5% iodoacetamide. SDS-PAGE was carried out on 15%
acrylamide gels at 30 mA/gel using a Protean II xi Cell (Bio-
Rad) at 10°C, until the dye front reached the bottom of the gel.
2-DE analytical gels were stained by ammoniacal silver nitrate,
as previously described [25,26], while the preparative gels
were stained applying a MS-compatible silver staining protocol
[27]. Analytical and MS-preparative gels were then digitalized
using a GS-800 imaging densitometer (Bio-Rad).
At least three biological replicates with two technical
replicates were run for each tested condition and the resulting
protein maps were analyzed by PDQuest v 8.0.1 software (Bio-
Rad). Normalized spot volume values (Vol = integration of OD
over the spot area; Normalized Vol = Vol of a single spot
divided by the total spot Vol) were used for statistical
evaluation of protein abundance. The coefficient of variation
(CV, calculated by the standard deviation of the normalized
spot volumes divided by the mean, expressed as a percent)
and the correlation coefficient, as r2, of the normalized spot
volumes were calculated as a measure of within- and between-
sample variance
In-gel tryptic digestion and MS protein identification
Spots of interest were manually excised from MS-preparative
2-DE gels, destained and acetonitrile (ACN) dehydrated.
Successively, they were rehydrated with a trypsin solution
(Sigma-Aldrich) and in-gel digestion was carried out overnight
at 37°C. Protein digests (0.75 µl for each spot) were spotted
onto a MALDI-TOF target (GE Healthcare) and allowed to dry.
Then, 0.45 µl of matrix solution (saturated solution of α-
cyano-4-hydroxycinnamic acid in 50% v/v ACN and 0.5% v/v
trifluoroacetic acid (TFA)) was applied to the dried sample,
dried again and tryptic peptide masses were acquired on an
Ettan MALDI-ToF Pro mass spectrometer (GE Healthcare).
Mass spectra were acquired in reflectron mode with an
accelerating voltage of 20 kV using the Ettan MALDI Evaluation
software (GE Healthcare). Peptide masses were internally
calibrated using the 842.509 and 2211.105 m/z trypsin
autolysis peptides. All the obtained mass lists were
automatically cleaned up from eventually present contaminant
masses, such as those from matrix, auto-digestion of trypsin,
and keratins. Protein identification was carried out by peptide
mass fingerprinting searching in UniProtKB (SwissProt
2012_08: 537505 sequences (Rattus: 7800 sequences);
190795142 residues) and NCBInr (NCBInr 20120922:
20543454 sequences (Rattus: 68040 sequences); 7050788919
residues) databases using Mascot (Matrix Science Ltd.,
London, UK, http://www.matrixscience.com) on-line-available
software. Searches were performed allowing a mass tolerance
of 100 ppm and a single missed cleavage site, with
carbamidomethyl cysteine as fixed modification and oxidized
methionine as variable modification. The taxonomy was limited
to Rattus norvegicus, whereas no restrictions on protein
molecular weight and pI values were applied. The criteria used
to accept identifications included the extent of sequence
coverage, number of matching peptides, and probabilistic score
sorted by the software, as detailed in Table S1.
In the case of ambiguous identifications, tryptic digests were
subjected to ESI-Ion trap MS/MS peptide sequencing on a
nanospray/LCQ DECA Ion Trap mass spectrometer (Thermo
Scientific, San Jose, CA, USA). Peptide samples were acidified
with 1% TFA, concentrated and desalted using mC18 Zip-Tips
(Millipore, Billerica, MA, USA). Tryptic peptide elution was
achieved with a 70% methanol and 0.5% formic acid solution
and concentrated samples were loaded in a distal coated
Fused-Silica Picotip emitter to be nanosprayed in the mass
spectrometer. The collision energy was set based on the mass
of the doubly charged precursor ions and spectra were
recorded using Xcalibur software (Thermo Scientific). Database
search of MS/MS spectra was performed by TurboSEQUEST
(Thermo Scientific) and Mascot MS/MS ion search software
(http://www.matrixscience.com) in UniProtKB and NCBInr non-
redundant databases. The following criteria were applied: MS
mass accuracy ± 1.2 Da, MS/MS mass accuracy ± 0.6 Da,
peptide precursor charge 2+, monoisotopic experimental mass
values, trypsin digestion with one accepted missed cleavage,
fixed carbamidomethylation of cysteine and variable oxidation
of methionine.
Bioinformatic analysis of the proteomic data
Only “reliable” protein spots were considered (i.e. given n
experimental replications per condition, a protein spot was kept
if at least (n-1) volume values were available for all samples)
and missing values were imputed using the k-nearest neighbor
(KNN) method (Matlab v 7.12.0, MathWorks, Torino, Italy).
Pairwise comparisons of protein spot abundances were
performed using Student’s t-test (SigmaStat v 3.5 software,
Systat Software, Point Richmond, CA, USA). A p value <0.05
was considered as statistically significant. Multivariate data
analysis methods were used for selecting significant spots and
classifying the different group samples. Principal Component
Analysis (PCA) was carried out using CANOCO for Windows v
4.5. All variables were centered and weighted by (standard
deviation)-1.
Significant differences were analyzed through the two-way
hierarchical clustering methodology using PermutMatrix v 1.9.3
software (http://www.lirmm.fr/~caraux/PermutMatrix/). Samples
were clustered employing the Pearson and Ward’s minimum
variance methods for distance and aggregation, respectively.
Identified proteins were annotated using the publicly
available on-line Gene Ontology (GO) database, AmiGO
version 1.8 (database release 31-03-2012; http://
amigo.geneontology.org), which standardizes the
representation of genes and their products by using a
controlled vocabulary in terms of location, biological processes
and molecular function. Protein accession numbers and their
corresponding fold changes were imported into the web-based
integrative software MetaCoreTM (v 6.8 build 30387; Thomson
Reuters, St. Joseph, MI, USA) for enrichment and network
analysis. The enrichment analysis of GeneGo pathway maps,
metabolic networks and process networks was based on
hypergeometric distribution statistics. The network building of
the dysregulated proteins was carried out using the shortest
path algorithm and its variants. Networks were ranked
according to their statistical significance (p<0.001) and
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interpreted in terms of GO. Major hubs were delineated based
on the connections and edges within the networks.
Functional analysis of proteomic data
Protein accession numbers of the MS-identified differentially
expressed proteins and their corresponding fold changes were
imported into the web-based integrative software MetaCoreTM
(v 6.8 build 30387; Thomson Reuters, St. Joseph, MI, USA) for
enrichment and network analysis. For detailed information see
Supplementary data online.
Western blot analysis
Differential expression of CLP36, GLO1 and MIF was
validated by western blotting. Protein samples were resolved in
10% acrylamide gels and then transferred onto nitrocellulose
membranes in a trans-blot electrophoresis transfer cell (Bio-
Rad). The following primary antibodies were used: anti-CLP36
(1:500), anti-GLO1 (1:500), anti-MIF (1:1000), and anti-β-actin
(1:5000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Assessment of cell viability and apoptosis
Cell viability was evaluated by measuring 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
reduction as previously reported [28]. Briefly, at the end of each
experiment, 0.5 mg/ml MTT was added and incubated for 1 h
at 37°C. After incubation, MTT solution was removed, 200 µl
DMSO was added, and the absorbance was measured at
λ=595 nm using a microplate spectrophotometer (VICTOR3 V
Multilabel Counter; Perkin-Elmer, Wellesley, MA, USA).
Detection of Intracellular Reactive Oxygen Species
levels (ROS)
Confocal microscopy.  ROS formation in cardiomyocytes
was visualized as follows. Cells were incubated with 5 μM SF
for 24 h, exposed to1 mM MG for 24 h, and then washed twice
with warm PBS, and DHE and MitoSOX were added to cells at
a final concentration of 5 µM. After incubation with DHE (20
min) and MitoSOX (10 min), cells were fixed with 4%
paraformaldehyde for 10 min, mounted onto glass slides with
Mowiol, and observed under a confocal microscope with
excitation and emission wavelengths set to 490 and 590 nm,
respectively [29,30]. All images were taken under identical
exposure conditions in order to evaluate the intensity of the
probe fluorescence accurately. Confocal imaging was
performed on a Nikon A1 confocal laser scanning microscope
as previously described [31]. The confocal serial sections were
processed with ImageJ software to obtain three-dimensional
projections, as previously described [32]. The image rendering
was performed by Adobe Photoshop software.
Spectrofluorimetric assays.  ROS producion was
evaluated using different fluorescent probes: DCFH-DA, DHE
and MitoSOX. Briefly, controls and SF-treated cells were
washed with PBS and then incubated with 5 μM DCFH-DA for
30 min. Next, cells were incubated with 1 mM MG. Cell
fluorescence was measured using a microplate
spectrofluorometer (VICTOR3 V Multilabel Counter) (λex/
em=485/535 nm) as previously reported [24]. Cells were
treated with 5 μM SF for 24 h and then exposed to 1 mM MG.
Cells were washed with PBS and incubated with 5 μM DHE for
20 min or 5 μM MitoSOX for 10 min at 37 °C. Cell fluorescence
was measured using a microplate spectrofluorometer
(VICTOR3 V Multilabel Counter) (λex/em=485/590 nm).
Total antioxidant activity (TAA).  TAA assay, performed as
previously reported [33], was used as an indirect index of
intracellular ROS production. Briefly, at the end of each
experiment, cardiomyocytes were washed 3 times with cold
PBS. Cells were lysated in PBS using a potter homogeniser
and centrifuged at 1000 g to remove cell debri. TAA was
determined by the decoloration of the radical cation ABTS, in
terms of quenching of absorbance at 740 nm. Values obtained
for each sample were compared with the concentration–
response curve of a standard Trolox solution, and expressed
as µmol of Trolox Equivalent Antioxidant Activity per mg of
protein (TEAA µmol/mg protein).
Caspase-3 activity assay
Caspase-3 activity was measured by means of a fluorimetric
assay based on the hydrolysis of the peptide substrate acetyl-
Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC)
by caspase-3, resulting in the release of the fluorescent 7-
amino-4-methylcoumarin (AMC) moiety as previously reported
[28]. Briefly, cells received 5 µM SF for 24 h and were
subsequently treated with 1 mM MG for further 24 h. At the end
of the treatment cells were washed twice with ice-cold PBS,
scraped off and incubated on ice in lysis buffer (50 mM HEPES
pH 7.4, 5 mM CHAPS and 5 mM DTT) for 20 min. Samples
were centrifuged at 15 000 g for 15 min at 4°C and protein
concentration in supernatants was determined according to the
Bradford method [24].
From each sample, 5 µl was transferred to a 96-well plate
and 200 µl of reaction mix (20 mM HEPES pH 7.4, 0.1%
CHAPS, 5 mM DTT and 2 mM EDTA) containing Ac-DEVD-
AMC (final concentration 16 µM), was added to each well.
Fluorescence intensity was recorded every 5 min for 1 h by a
microplate spectrofluorometer (λex/em= 360/460 nm). Caspase
activity was calculated using a AMC standard curve and results
were expressed as nmol AMC/min/mg protein.
GLO1 activity assay
Cardiomyocyte GLO1 activity was assessed by
spectrophotometry according to the method of McLellan and
Thornalley [34] with minor modifications. Briefly, cells were
lysed in 10 mM PBS and protein concentrations were
estimated using the Bradford’s method [24], GLO1 activity
assay was performed by addition of 20 μl of cell lysate to a
reaction mixture containing 2 mM MG and 2 mM GSH, which
had been equilibrated for 10 min before sample addition.
AGE assay
AGE protein adducts were quantified by the OxiSelect™
AGE ELISA Kit (Cell Biolabs, San Diego, CA, USA) according
to manufacturers’ instructions.
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Statistics
Each experiment was performed at least three times, and all
values are represented as mean ± SD. Statistical analysis was
performed with Student’s t-test and one-way ANOVA followed
by Dunnett’s or Bonferroni’s test (Prism 5; GraphPad Software,
San Diego, CA, USA). Statistical significance was considered
to be achieved when p<0.05. For statistical analysis of
proteomic data see Supplementary data online.
Results
Time-course proteomic profiling of SF-treated
cardiomyocytes
To gain insights into the molecular pathways modulated by
SF, time-dependent differential protein expression profiles of
cardiomyocytes treated with SF were investigated.
Cardiomyocytes were exposed to 5 µM SF for 1-48 h, and for
each sampled time point, protein extracts were resolved
applying 2-DE. Cardiomyocytes treated with 0.05% DMSO
(vehicle control) were used as a control. Representative silver-
stained 2-DE gels of DMSO- and SF-treated cardiomyocytes
are shown in Figure 1. In each gel more than 800 spots were
detected, quantified, normalized and inter-gel matched. The
mean CV for normalized spot volumes was determined to be
18% for the analytical variance and 41% for the biological
variance. The mean r2 values for within-sample comparisons
ranged from 0.78 to 0.88. The r2 values for between-sample
comparisons were 0.72 to 0.80. The entire 2-DE dataset was
processed using the unsupervised multivariate method PCA.
PCA revealed a generally consistent reproducibility between
the biological replicates and a non-linear behavior during the
time course (Figure 2A). The first two PCs accounted for about
55% of the total variance in the data (36.8 and 17.8% for PC1
and PC2, respectively). Interestingly, the protein patterns of 1 h
SF-treated cardiomyocytes were clearly segregated from
DMSO control, suggesting that significant changes in protein
expression occurred early after SF exposure. Conversely, spot
maps at 6 and 24 h were almost completely overlapped,
indicating that no additional differences in the SF-treated
cardiomyocyte proteome occurred during this time interval.
After 48 h, a clearly different protein expression profile was
evidenced.
In addition to multivariate analysis, pair-wise comparisons of
individual protein spots were performed using Student’s t-test
and the non-parametric Mann-Whitney test. Protein expression
changes were considered significant when relative spot
abundance increased or decreased by at least 1.5-fold
between DMSO control and the different time points with
p<0.05. Sixty four significant variations were found. Differential
spots were clustered using Ward’s minimum variance method
over a Pearson distance-based dissimilarity matrix. As shown
in Figure 2B and S1, spot maps were generally partitioned
according to the experimental sample set, except for the
overlaps between the expression profiles at 24 and 48 h. Two
main clusters were recognized, each subdivided in at least 3
sub-clusters. In particular, clusters I and II included 14 and 8
proteins, respectively, whose abundance dramatically
decreased after 6 h SF treatment before returning to baseline
levels at later time points. Analogously, the 11 cluster III
proteins were up-regulated in DMSO- and 1 h SF-treated
cardiomyocytes, but down-regulated at 6 h. Conversely, the
other three clusters (IV-VI) grouped 12, 8 and 11 protein spots,
respectively, whose expression levels increased over time after
SF treatment.
Following Mascot database search using acquired MS data,
47/64 (73%) protein spots were successfully identified,
corresponding to 41 unique proteins. Details of the protein
identification, protein score, sequence coverage, theoretical/
experimental pI value and molecular weight as well as average
relative change at each treatment time point are summarized in
Table S1. Representative spectra and mass lists for three
identified protein spots are shown in Figure S2. Identified
proteins were categorized according to ontological categories
(http://amigo.geneontology.org; Figure 2C,D,E and Table S2).
The most represented biological processes were transcription/
translation (12%), oxidation-reduction process/cell redox
homeostasis (10%), glycolysis (10%), protein folding (7%), and
anti-apoptosis (7%). More than half of the SF responsive
proteins (61%) were cytoplasmic. Endoplasmic reticulum
accounted for 15% of the identifications, whereas mitochondrial
proteins were 10%. According to molecular function, as much
as 68% of the significantly modulated proteins were classified
as binding proteins. In particular, nearly one-third of affected
proteins were involved in calcium ion and protein binding.
Twelve percent were related to catalytic activity. Expression
profiles of proteins comprised in Figure 2E are shown in
supplementary material (Figure S3).
Pathways and networks involving the differentially expressed
proteins were analyzed using MetaCore. Enrichment analysis
revealed that the most enriched pathways (Figure S4A) and
metabolic networks (Figure S4B) were related to glycolysis and
gluconeogenesis. Additionally, enrichment in the ontology of
functional processes, as defined by “GeneGo process
networks”, was calculated. Regulation of cytoskeleton
rearrangement and protein folding resulted as top-scoring
networks (Figure S4C).
To map interaction between proteins, the shortest direct
paths were performed using the “analyze network” algorithm.
Based on the functional sub-networks built, the SF responsive
proteins were primarily involved in signaling pathways (p =
5.13×10-26), as well as regulation of immune response (p =
2.89×10-8) (Table S3). Then, to identify specific transcription
factors which could drive the proteome changes in SF-treated
cardiomyocytes, a variant of the “shortest paths” algorithm was
used to generate transcriptional regulation networks. SP1 was
ranked #1, with 24 targets among the 41 identified proteins
from 2-DE gels (Figure 3). The regulation mechanisms of 13/24
SP1 targets were unknown. Other top-scoring transcriptional
regulators were c-Myc and p53 (Table S4).
Validation of time-dependent differential expression of
MIF, CLP36 and GLO1
Validation of proteomics findings by western blot analysis
was performed to confirm the differential expression of MIF,
CLP36 and GLO1. These proteins were selected for both their
increased expression after SF treatment and their possible
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involvement in SF-induced cardioprotection [12,17]. In
particular, it has recently been shown that MIF provides
cardioprotection during I/R by reducing oxidative stress [35],
that CLP36 plays an important role in heart development [36],
and that GLO1 is an enzymatic defence against α-
oxoaldehyde-mediated glycation [13].
Representative immunoblots of MIF, CLP36 and GLO1
together with densitometric quantifications of the spots
obtained by proteomic analysis are shown in Figure 4.
Consistent with 2-DE maps, the expression of MIF was
markedly elevated already after 1 h SF treatment. Similar
results were obtained for CLP36, while GLO1 expression was
higher than DMSO control after 6 h treatment. All these
increases in protein level lasted until 48 h after SF addition.
SF protection against MG-induced damage
To better understand the role of SF-induced GLO1 up-
regulation, we studied the protective effects of SF against MG,
the main GLO1 substrate, in cardiomyocytes. First of all, IC50
for MG cytotoxicity was determined. Cardiomyocytes were
treated with increasing concentration of MG (0.1-5 mM) and the
MTT viability assay was performed after 24 h (Figure S5). One
mM MG was considered as IC50 value and used in the
subsequent experiments. To evaluate the ability of SF to
Figure 1.  2-DE protein profile of cardiomyocytes treated with SF.  IEF performed on IPG strips (13 cm, 3-10 linear pH gradient)
was followed by second dimension separation on a 15% polyacrylamide gel. 2-DE gel was silver-stained. Identified spots, showing a
statistically significant difference of at least 1.5-fold between SF-treated cardiomyocytes at different time points [1 (B), 6 (C), 24 (D)
and 48 (E) h] and vehicle control (A), are numbered (Table S1). Circles and squares indicate up- and down-regulated protein spots,
respectively. (A) Diamonds indicate protein spots with opposite trends of expression among the time points of exposure to SF.
doi: 10.1371/journal.pone.0083283.g001
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Figure 2.  Multivariate analysis of proteomic data.  (A) PCA plot of the protein spot maps of cardiomyocytes untreated (DMSO
vehicle control; circles) and after exposure to SF for 1 (triangles), 6 (squares), 24 (diamonds) and 48 h (crosses). Log-transformed
data were used. Each symbol represents a 2-DE gel from each treatment series. First and second ordination axes are plotted
explaining 36.8 and 17.8% of the overall variance in the dataset, respectively. (B) Two-way hierarchical clustering of the 64
differentially expressed protein spots between SF-treated cardiomyocytes and DMSO vehicle control. Pearson's dissimilarity as
distance measure and Ward's method for linkage analysis were used. Log2 ratios are colour coded as indicated. Names of the
identified protein spots are shown on the right (see Table S1). A larger version of this image with gene names and spot IDs in
brackets is available as Figure S1. (C-E) Functional categories by Gene Ontology (GO) analysis of the identified proteins.
Classification was performed according to keyword categories [(C) biological process, (D) cellular component, (E) molecular
function]. When proteins were associated with more than one functional category, one GO term was chosen arbitrarily. NA, not
available. ER, endoplasmic reticulum.
doi: 10.1371/journal.pone.0083283.g002
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protect cardiomyocytes from MG-induced damage, cells were
pre-treated with 5 µM SF for 24 h and subsequently exposed to
1 mM MG for further 24 h before MTT viability assay. As shown
in Figure 5A, SF was able to counteract MG-induced damage,
significantly increasing cell viability with respect to MG.
Moreover, caspase-3 activity assay and immunoblotting
analysis of caspase-3 expression revealed that SF markedly
protected cardiomyocytes against apoptosis induced by MG. In
figure 5B caspase-3 activity in cardiomyocytes pre-treated with
5 µM SF for 24 h and then exposed to 1 mM MG for further 24
h is reported. MG strongly increased caspase-3 activity
compared to control cells, evidencing a strong MG-induced
apoptotic cell death, whereas SF pre-treatment significantly
reduced this increase. These data were confirmed by
immunoblotting of caspase-3 (Figure 5C), which showed the
appearance of the activated caspase-3 fragment and the
corresponding decrease of pro-caspase-3 after MG treatment.
SF pre-treatment reduced the protein level of activated
caspase-3 with respect to MG-treated cells.
GLO1 is a GSH-dependent enzyme and excess MG
presents serious toxic effects since it depletes GSH via a
covalent bond. As GSH is one of the most important
endogenous antioxidant molecules, its depletion could be
related to an increase in ROS. To verify this hypothesis we
used 3 different probes, DCHF-DA, DHE, and MitoSOX as it is
widely accepted that a single readout for ROS generation is not
appropriate [37]. Representative confocal fluorescent
micrographs of cardiomyocytes pre-treated with 5 µM SF for 24
h, exposed to 1 mM MG and stained with DHE or MitoSox are
shown in Figure 6. MG induced a marked increase in DHE and
MitoSox fluorescence intensity, while SF was able to maintain
fluorescence intensity to value comparable to control cells. SF
alone had no effect on fluorescence intensity of cells stained
with DHE and MitoSox. Semi-quantitative measurements by
fluorescent plate reader of DCHF-DA, DHE and MitoSox
stained cardiomyocytes are reported in Figure 7. MG exposure
induced a significant increase in intracellular ROS levels. In
particular, the highest increase was obtained with DCHF-DA,
the less specific probe able to detect not only H2O2 but also
several one-electron-oxidizing species [37] (Figure 7A). In
agreement with the results obtained by confocal microscopy,
MG treatment significantly increased the fluorescence intensity
of DHE and MitoSox that more specifically target superoxide
(Figure 7B and C). SF was able to counteract the intracellular
ROS level increase induced by MG, maintaining fluorescence
intensity of the 3 probes to levels comparable to control cells.
To better elucidate SF role in counteracting oxidative stress,
total antioxidant activity (TAA) by ABTS assay was evaluated
(Figure 8). SF alone was able to significantly increase TAA in
respect to control cells, while MG significantly reduced this
value. Interestingly, SF was able to restore TAA levels of MG
treated cardiomyocytes to values comparable to control cells.
Figure 3.  Network analysis of differentially expressed proteins.  The top score transcription regulation network initiated through
activation of SP1 is shown. Network proteins are visualized by proper symbols, which specify the functional nature of the protein
(network caption). Green and gray arrows indicate positive and unspecified effects, respectively. Red and blue circles indicate up-
and down-regulated proteins following SF treatment, respectively. ‘Checkerboard’ color indicates mixed expression between files.
doi: 10.1371/journal.pone.0083283.g003
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Figure 4.  Validation of MS results by
immunoblotting.  Cardiomyocytes were treated with 5 μM SF
for 1-48 h followed by western blot analysis for MIF (A), CLP36
(B), and GLO1 (C). Representative bands and raw
densitometric values of the corresponding protein spots from
proteomic analysis are shown. Each bar represents the spot
quantity as determined by PDQuest (mean ± SD). At least
three biological replicates with two technical replicates were
run for each tested condition.
doi: 10.1371/journal.pone.0083283.g004
Effect of SF against MG-induced glycation
To relate GLO1 overexpression to its functional activity,
cardiomyocytes were treated with 5 µM SF and GLO1
enzymatic activity was measured at different time points (1-48
h) (Figure 9A). After 1 and 6 h GLO1 activity was slightly
increased but not significantly different from control cells. After
24 and 48 h SF was able to significantly increase GLO1 activity
with respect to untreated cells. Figure 9B shows the effect of 1
mM MG for 24 h in the absence/presence of SF. Interestingly
MG alone reduced GLO1 activity while SF pre-treatment was
able to maintain GLO1 activity at level comparable to control
cells. To demonstrate a direct effect of SF against MG-induced
glycation, we measured AGE production in cardiomyocytes
pre-treated with 5 µM SF for 24 h before exposure to 1 mM
MG. Figure 9C shows that, as expected, SF did not modify
AGE production with respect to control cells. On the contrary,
MG strongly increased AGE production, demonstrating its
ability to induce glycative stress. Interestingly, SF pre-treatment
was able to significantly reduce AGE production compared to
MG-treated cell.
Discussion
SF has shown cardioprotective activity in different in vitro
and in vivo models [12,38] but its multiple mechanisms of
action are not yet fully understood. The goal of this study was
to identify SF target proteins and mechanisms implicated in
cardioprotection. A 2-DE-based proteomics approach was
employed to profile the proteins affected by SF, leading to the
identification of 41 distinct proteins with altered expression,
which were associated with diverse biological functions. Most
of these proteins, such as Elfin, Vimentin, Calreticulin, S100
calcium-binding proteins, Tropomyosin chains TPM2 and
TPM4 were evidenced to be binding proteins. Twelve percent
of SF responsive proteins, such as Peroxiredoxin-6,
Phosphoglycerate mutase 1, Superoxide dismutase 1 and
Fructose-bisphosphate aldolase were associated with catalytic
activity.
Unexpectedly, proteomic analysis did not reveal the
modulation of glutathione reductase (GR), glutathione-S-
transferase (GST), NAD(P)H:quinone oxidoreductase-1
(NQO1), and thioredoxin reductase (TR) although in a previous
study we reported their induction by SF [12]. Regarding GR
and TR, we previously observed an increase in protein
abundance less than 2-fold compared to the control, so it is not
surprising we did not find GR and TR differentially expressed in
our proteomic study because we chose only protein spots with
a fold change of at least ± 1.5-fold compared to control. On the
contrary, based on the results of our previous work, we
expected to identify GST and NQO1 as they were strongly up-
regulated by SF. The failure of not finding them could be
ascribed to the different extraction protocols that may have
impacted on the yield of these specific enzymes and molecular
weight/isoelectric point. Our 2-DE maps are generally well
resolved at those values of molecular weight and isoelectric
points but we cannot exclude that those enzymes, as well as
other proteins, have undergone posttranslational modifications
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Figure 5.  SF protection against MG-induced damage.  Cardiomyocytes were treated with 5 µM SF for 24 h before addition of 1
mM MG. (A) Cell viability was assessed by MTT assay and reported as percent cell viability in comparison to control. (B) Caspase-3
activity was measured spectrofluorimetrically by hydrolysis of the peptide substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-
methylcoumarin (Ac-DEVD-AMC). (C) Cell lysates were immunoblotted with caspase-3 antibody that detects both full length
caspase-3 (35 kDa) and the large fragment of caspase-3 resulting from cleavage (17 kDa). Data are presented as mean ± SD, n = 4
in each group,* p<0.05 vs Control; ° p<0.05 vs MG.
doi: 10.1371/journal.pone.0083283.g005
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Figure 6.  Confocal microscopy analysis of SF effect on MG-induced ROS production.  Cardiomyocytes were treated with 5
µM SF for 24 h before the addition of 1 mM MG. Cytosolic ROS production was measured using DHE and mitochondrial ROS
production by MitoSOX staining. Scale bar: 10 µm.
doi: 10.1371/journal.pone.0083283.g006
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Figure 7.  Fluorimetric assays of SF effect on MG-induced ROS generation.  Cardiomyocytes were treated with 5 µM SF for 24
h before addition of 1 mM MG. (A) Intracellular ROS levels were determined with the peroxide-sensitive probe DCFH-DA. (B)
Cytosolic ROS levels were determined with DHE. (C) Mitochondrial ROS levels were determined with MitoSox. Data are expressed
as a percentage compared to control and are presented as mean ± SD, n = 4 in each group,* p<0.05 vs Control; ° p<0.05 vs MG.
doi: 10.1371/journal.pone.0083283.g007
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with important shifts towards low-resolution gel regions with
overlapping, less defined and/or separated spots.
Among the 41 identified proteins, we focused our attention
on 3 of these proteins because of their possible involvement in
multiple cellular pathways related to cardioprotection (e.g.
apoptosis, detoxification, antioxidant activity, cytoskeleton
stability): MIF, CLP36, and GLO1.
MIF has emerged as a key player in cardiovascular diseases
[39,40]. An up-regulation of myocardial MIF expression has
been observed in surviving cardiomyocytes and macrophages
in a rat model of acute myocardial ischemic injury [41]. MIF has
also been reported to be released by ischemic heart tissue and
to activate the cardioprotective AMP-activated protein kinase
(AMPK) pathway [42]. MIF is characterized by two conserved
sequence motifs that have been found to represent local
catalytic centres responsible for two distinct enzymatic
activities, a tautomerase/isomerase and a thiol-protein
oxidoreductase activity [43]. Several studies suggest that the
tautomerase/isomerase activity is related to its proinflammatory
function [44], whereas its oxidoreductase activity may play a
role in regulating cellular redox homeostasis [45]. Recently,
Koga et al. [35] provided the first in vivo evidence supporting a
role for the oxidoreductase function of MIF in mediating
cardioprotection during I/R by reducing the oxidative
environment of the myocardium. Moreover, it has been
reported that a number of isothiocyanates, including SF,
potently and irreversibly inactivate the MIF tautomerase
enzymatic activity [46]. In particular, studies using neutralizing
antibodies or MIF deficient animals showed that inhibition of
MIF can ameliorate disease development in animal models of
inflammatory bowel disease and arthritis [47,48]. Our data, for
the first time, demonstrated that SF, besides its reported ability
Figure 8.  SF effects on cardiomyocytes total antioxidant
activity.  Cardiomyocytes were treated with 5 µM SF for 24 h
before addition of 1 mM MG. Cell lysates were submitted to the
ABTS radical cation decolorization assay and the antioxidant
activity of the cells were expressed as mean ± SD of µmol of
trolox antioxidant activity per mg of protein. p<0.05 vs Control;
° p<0.05 vs MG.
doi: 10.1371/journal.pone.0083283.g008
to inhibit MIF tautomerase activity, increases MIF protein level
probably boosting its protective oxidoreductase activity. This
result is very important because it could contribute to explain
the previously demonstrated SF cardioprotective effect against
oxidative stress [12,17]. Further studies will be necessary to
better clarify the exact role of MIF enzymatic activity in
cardioprotection.
CLP36 (CLIM1, Elfin, PDLIM1) is a member of the ALP/
Enigma protein family [49] that serves as scaffolding proteins at
the actin cytoskeleton. CLP36 contains a N-terminal PDZ
domain and a C-terminal LIM domain and is abundantly
expressed in the heart [50]. Although the physiological
functions of CLP36 are not fully elucidated, several proteins
have been shown to interact with cytoskeletal proteins through
their PDZ domain and also with intracellular kinases through
their LIM domain(s) [51]. In particular, it has been observed
that CLP36 recruits the Clik1 kinase to actin cytoskeleton and
this association is mediated through a bridge formed by the
PDZ-LIM protein and α-actinin [52]. In a previous work we
demonstrated that hypoxia is able to impair cardiomyocyte
actin organization [53], so it could be hypothesized that SF up-
regulation of CLP36 is involved in the maintenance of the
cytoskeleton structure integrity.
GLO1 is part of the glyoxalase system that catalyses the
conversion of reactive, acyclic α-oxoaldehydes into the
corresponding α-hydroxyacids [13]. The main physiological
GLO1 substrate is MG, and this accumulates markedly when
the enzyme is inhibited in situ by cell-permeable GLO1
inhibitors and by depletion of GSH [54]. MG, a highly reactive
carbonyl compound generated by carbohydrate oxidation and
glycolysis, is the major precursor of protein glycation [16]. MG
is more reactive than its parent sugar glucose, showing a
stronger ability to cross-link with protein amino groups to form
AGEs [55]. The accumulation of AGEs has been closely
associated with chronic diseases caused by either or both
hyperglycemia and oxidative stress [56,57]. It has been
observed that MG-AGEs induced cardiac myocyte injury
accompanied with temporal activation of ERK1/2, p38 MAPK
and nuclear O-GlcNAcylation, indicating their potential roles in
the AGE-triggered ROS generation and apoptosis [58]. Our
data confirmed MG deleterious effect on cardiomyocytes,
moreover, for the first time, we demonstrated that SF
counteracted MG-induced apoptotic cell death, reduced ROS
generation and AGE production, and induced GLO1 expression
and functional activity. Likely, SF elicits a multi-target behavior
against MG-induced damage: it up-regulates GLO1 enhancing
the cell ability to detoxify MG, and acts as an indirect
antioxidant reducing ROS produced by MG. Even if the exact
role of the glyoxalase system in cardiovascular disease has not
been fully elucidated, it has been observed that in hemodialysis
patients, the GLO1 A419C polymorphism is associated with a
significantly higher prevalence of cardiovascular disease and
peripheral vascular disease risk [59]. Moreover, Wang et al.
[60] demonstrated that thioredoxin activity was decreased due
to post-translational glycative modification in cardiomyocytes
treated with MG and blocking AGE production inhibited
thioredoxin inactivation and significantly protected
cardiomyocytes from I/R injury. These results suggest that any
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Figure 9.  Effect of SF against MG-induced glycation.  (A) Cardiomyocytes were treated with 5 µM SF for different time intervals
(1-48 h) and GLO1 enzyme activity was measured by a spectrophotometric method. (B) Cardiomyocytes were treated with 5 µM SF
for 24 h before addition of 1 mM MG, and GLO1 enzyme activity was measured by a spectrophotometric method. (C)
Cardiomyocytes were treated with 5 µM SF for 24 h before addition of 1 mM MG, and AGE formation was evaluated by AGE-ELISA
using a specific anti-AGE antibody. Data are presented as mean ± SD, n = 4 in each group, * p<0.05 vs Control; ° p<0.05 vs MG.
doi: 10.1371/journal.pone.0083283.g009
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intervention able to reduce intracellular MG concentration, like
GLO1 induction by SF treatment, could attenuate injury
endured in myocardial I/R processes.
In conclusion, the identification of proteins with altered
expression profiles at multiple treatment time points may serve
to elucidate the cellular mechanisms involved in the response
to SF in cardiac cells. In particular, the up-regulation of MIF,
CLP36 and GLO1, which are associated with anti-apoptotic,
cytoskeleton binding, and detoxifying activities, gives new
insights into the understanding of SF pleiotropic behavior in
counteracting cardiovascular diseases.
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